Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2015

01-12-2015 | Meeting abstract

Telmisartan, when compared to losartan, shows additional beneficial effects to pancreatic islet structure and function in diet-induced obese mice

Authors: Francielle Graus-Nunes, Felipe de Olivera Santos, Thatiany de Souza Marinho, D'Angelo Carlo Magliano, Fernanda Ornellas, Marcia Barbosa Aguila, Carlos Alberto Mandarim de Lacerda, Vanessa de Souza Mello

Published in: Diabetology & Metabolic Syndrome | Special Issue 1/2015

Login to get access

Excerpt

In animal studies, telmisartan elicits weight loss by activation of the peroxisome proliferator-activated receptors (PPARs), besides blocking AT1-r downstream effects. The effects of telmisartan upon pancreatic islets remain to be unraveled. …
Metadata
Title
Telmisartan, when compared to losartan, shows additional beneficial effects to pancreatic islet structure and function in diet-induced obese mice
Authors
Francielle Graus-Nunes
Felipe de Olivera Santos
Thatiany de Souza Marinho
D'Angelo Carlo Magliano
Fernanda Ornellas
Marcia Barbosa Aguila
Carlos Alberto Mandarim de Lacerda
Vanessa de Souza Mello
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue Special Issue 1/2015
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/1758-5996-7-S1-A120

Other articles of this Special Issue 1/2015

Diabetology & Metabolic Syndrome 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine